GenCefe Biotech is excited to announce that we will attend the EACR Congress 2026, one of Europe's leading conferences dedicated to cancer research and innovation.

Our representatives will join researchers, clinicians, and industry professionals from around the world to discuss the latest developments in cancer biology, translational research, precision medicine, immuno-oncology, and emerging therapeutic technologies.

As a trusted partner for life science research, GenCefe Biotech provides a broad range of services including gene synthesis, DNA/RNA synthesis, IVT mRNA production, peptide synthesis, cell-free protein expression, and customized solutions designed to accelerate scientific discovery and drug development.

Attending EACR 2026 reflects our ongoing commitment to engaging with the global research community and supporting cutting-edge cancer research through reliable and innovative scientific services.

We look forward to meeting current and prospective partners during the congress and discussing how GenCefe Biotech can contribute to your research success.

About EACR Congress 2026

The EACR Congress is organized by the European Association for Cancer Research and is one of Europe's leading cancer research conferences. The congress brings together researchers, clinicians, and industry experts from around the world to share advances in cancer biology, translational oncology, immunotherapy, precision medicine, and emerging therapeutic approaches.

About GenCefe Biotech

GenCefe Biotech provides integrated solutions covering gene synthesis, DNA/RNA oligonucleotide synthesis, IVT mRNA production, peptide synthesis, cell-free protein expression, and custom molecular biology services. With ISO 9001 and ISO 13485 certified quality management systems, GenCefe supports researchers and biotechnology companies worldwide with reliable, high-quality products and services that accelerate scientific discovery and therapeutic development.